Back to search
FDAFDA · Food and drugs·Recall number D-1451-2016

mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial packaged in a carton, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.

Published August 3, 2016 · Recall initiated: May 31, 2016

Summary

FDA records drug Class III recall D-1451-2016, published August 3, 2016 and initiated May 31, 2016. Recalling firm: Teva North America; Status: Terminated; Reported quantity: 2,506 vials; Lot: Lot # 31318659B, Exp 02/17. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: High out of specification results for Impurity D.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva North America
Distributor
Nationwide
Lot
Lot # 31318659B, Exp 02/17
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial packaged in a carton, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01. recalled?

Yes. FDA published recall D-1451-2016 on August 3, 2016. Reported hazard: Failed Impurities/Degradation Specifications: High out of specification results for Impurity D.

What should I do if I have this product?

Voluntary: Firm initiated · Letter